GU Cancers 2020 | EV-101: enfortumab vedotin for UC

Name: EV-101: enfortumab vedotin for UC
Uploaded: 2020-02-15T17:00:01Z
Description: Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses results from the recent EV-101 study (NCT02091999), assessing the use of enfortumab vedotin in patients with metastatic urothelial carcinoma (UC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Daniel Petrylak • 15 Feb 2020

GU Cancers 2020

Bladder Cancer Genitourinary Cancer Antibodies Checkpoint Inhibitors Enfortumab vedotin

EV-101

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses results from the recent EV-101 study (NCT02091999), assessing the use of enfortumab vedotin in patients with metastatic urothelial carcinoma (UC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.